Date de publication: 31 mai 2013
Promoteur – Intermédiaire Financier
H. LUNDBECK A/SLieu
Description
Financing Lundbeck’s Neurology R&D for the 2013-2015 period for the development of new innovative patented drugs for the treatment of CNS diseases with high unmet medical need.
Objectifs
The project concerns the research and development (R&D) activities oriented towards disorders of the central nervous system including Parkinson’s and Alzheimer ’s disease, whereby a defect of the synaptic transmission within the nerve cells is a cause of the disease. It covers different stages of development including pre-clinical and clinical studies.
Secteur(s)
Montant BEI envisagé (montant approximatif)
EUR 150 million
Coût total (montant approximatif)
EUR 392 million
Aspects environnementaux
The project mainly concerns investments in R&D that are expected to be carried out in existing facilities already authorized for the same purpose and would therefore not require an Environmental Impact Assessment (EIA) under the Directive 2011/92/EU. Full environmental details will be verified during the appraisal.
Passation des marchés
The promoter is a private company not operating in the Utilities sector and not having the status of a contracting authority. Thus it is not covered by EU Directives on procurement.
Statut
Signé - 23/10/2013
Clause de non-responsabilité
Avant d’être approuvés par le Conseil d’administration et avant la signature des prêts correspondants, les projets font l’objet d’une instruction et de négociations. Par conséquent, les informations et données fournies sur cette page sont indicatives.
Elles sont fournies à des fins de transparence uniquement et ne peuvent être considérées comme représentant la politique officielle de la BEI (voir également les notes explicatives).